Expansion & Markets Mirxes is rapidly expanding beyond Singapore with operations and distribution across the USA, Japan, and China and a global sales network, presenting opportunities to cross-sell at-home and multi-cancer tests to international healthcare providers, hospitals, and clinics.

Early Cancer Focus GASTROClear and the growing early detection portfolio across lung, thyroid, colorectal, breast, liver, and ovarian cancers position Mirxes to partner with payers, health systems, and labs seeking proactive screening programs and population health initiatives.

Public Funding & IPO Recent IPO and substantial financing events underline strong growth traction and investor confidence, creating dialogue opportunities with regional distributors, strategic partners, and healthcare technology integrators seeking scalable diagnostic platforms.

Clinical & Tech Edge Rooted in the ID3EAL microRNA discovery platform and qPCR-based diagnostics, Mirxes offers collaboration potential with academic medical centers, biopharma, and CROs for biomarker discovery, assay development, and companion diagnostics.

COVID-19 Network Established manufacturing and distribution networks from the Fortitude RT-PCR program across 45 countries and 13 Singapore hospitals can be leveraged to accelerate multi-cancer screening rollouts and at-home testing adoption with healthcare providers and retailers.